Table 2. Common genomic aberrations in metastatic prostate cancer.
| Gene | mCRPC
altered, percentage |
Chromosome | Type of
mutation |
|---|---|---|---|
| AR | 61 | Xq | Amp/Mut |
| ETS family a | 49 | - | Fusion/Amp |
| ERG | 35 | 21q | Fusion |
| TP53 | 47 | 17p | Homdel/Mut |
| PTEN | 43 | 10q | Homdel/Mut |
| HEY1 | 21 | 8q | Amp |
| E2F5 | 21 | 8q | Amp |
| MYC | 20 | 8q | Amp |
| RB1 | 17 | 13q | Homdel/Mut |
| FOXA1 | 14 | 14q | Amp/Mut |
| CHD1 | 11 | 5q | Homdel/Mut |
| FOXO1 | 11 | 13q | Homdel/Mut |
| BRCA2 | 11 | 13q | Homdel/Mut |
| MED12 | 9 | Xq | Amp/Mut |
| SPOP | 8 | 17q | Mut |
| ATM | 8 | 11q | Homdel/Mut |
| PIK3CA | 8 | 3q | Amp/Mut |
| CDK12 | 5 | 17q | Mut |
A selection of common alterations in metastatic castration-resistant prostate cancer (mCRPC). cBioPortal 34, 35 was used to query three mCRPC data sets containing 347 tumors from 263 patients 27– 29. The second column shows the percentage of patients with a tumor carrying the alteration. Data were queried specifically for the type of alterations listed in the third column. Amp, genomic amplification; Homdel, homozygous deletion; Mut, nonsynonymous mutation. a ERG, ETV1/4/5, FLI1.